# SHR6390 Combined With Anastrozole for Preoperative Treatment of Breast Cancer.

> **NCT04836520** · PHASE2 · COMPLETED · sponsor: **Tianjin Medical University Cancer Institute and Hospital** · enrollment: 20 (actual)

## Conditions studied

- Breast Cancer

## Interventions

- **DRUG:** SHR6390+anatrozole

## Key facts

- **NCT ID:** NCT04836520
- **Lead sponsor:** Tianjin Medical University Cancer Institute and Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2021-08-02
- **Primary completion:** 2023-02-28
- **Final completion:** 2023-03-31
- **Target enrollment:** 20 (ACTUAL)
- **Last updated:** 2023-04-12

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04836520

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04836520, "SHR6390 Combined With Anastrozole for Preoperative Treatment of Breast Cancer.". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT04836520. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*